Pfizer's Bosulif set for EU approval in CML
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended that Pfizer's oral Bcr-Abl kinase inhibitor bosutinib (Bosulif 100mg and 500mg) be granted conditional marketing authorisation for the treatment of chronic myelogenous leukaemia (CML).